Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial

• Jian Zhang ,

  Contributed equally to this work with: Jian Zhang, Yanchun Meng

  Roles Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing – review & editing

  * E-mail: syner2000@163.com (JZ); xchu2009@hotmail.com (XH)

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

  https://orcid.org/0000-0003-3208-3106

  ⨯
• Yanchun Meng ,

  Contributed equally to this work with: Jian Zhang, Yanchun Meng

  Roles Data curation, Formal analysis, Investigation, Project administration, Writing – original draft

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

  ⨯
• Biyun Wang,

  Roles Data curation, Investigation

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

  ⨯
• Xinhong Wu,

  Roles Investigation

  Affiliation Department of Breast Oncology, Hubei Cancer Hospital, Wuhan, China

  ⨯
• Hongmei Zheng,

  Roles Investigation

  Affiliation Department of Breast Oncology, Hubei Cancer Hospital, Wuhan, China

  ⨯
• Jing Hu,

  Roles Investigation

  Affiliation Department of Medical Oncology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China

  ⨯
• Wei Liu,

  Roles Investigation

  Affiliation Department of Medical Oncology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China

  ⨯
• Wenyan Chen,

  Roles Investigation

  Affiliation Department of Medical Oncology, Nanchang People’s Hospital, Nanchang, China

  ⨯
• Leiping Wang,

  Roles Investigation

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

  ⨯
• Jun Cao,

  Roles Data curation

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

  ⨯
• Zhonghua Tao,

  Roles Investigation

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

  ⨯
• Ting Li,

  Roles Data curation

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

  ⨯
• Sujie Ni,

  Roles Data curation, Investigation

  Affiliation Department of Medical Oncology, Affiliated Hospital of Nantong University, Nantong, China

  ⨯
• Zhengyan Yu,

  Roles Investigation

  Affiliation Department of Medical Oncology, Tumour Hospital of Mudanjiang City, Mudanjiang, China

  ⨯
• Lichun Sun,

  Roles Data curation

  Affiliation Department of Medical Oncology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, China

  ⨯
• Yun Wang,

  Roles Data curation

  Affiliation Department of Medical Oncology, Nanchang People’s Hospital, Nanchang, China

  ⨯
• Qiang Peng,

  Roles Data curation

  Affiliation Department of Medical Oncology, Nanchang People’s Hospital, Nanchang, China

  ⨯
• Song Wang,

  Roles Data curation

  Affiliation Department of Medical Oncology, Tumour Hospital of Mudanjiang City, Mudanjiang, China

  ⨯
• Xin Hu,

  Roles Data curation

  Affiliation Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai, China

  https://orcid.org/0000-0002-8160-8362

  ⨯
• Jianfei Wang,

  Roles Data curation

  Affiliation Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China

  ⨯
• Yijia Wu,

  Roles Data curation

  Affiliation Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China

  ⨯
•  [ ... ],
• Xichun Hu

  Roles Conceptualization, Investigation, Supervision

  * E-mail: syner2000@163.com (JZ); xchu2009@hotmail.com (XH)

  Affiliations Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

  https://orcid.org/0000-0002-9892-699X

  ⨯
• [ view all ]
• [ view less ]